MD — Pediatrix Medical Group, Inc.

Summary of Pediatrix Medical Group, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Adjusted EBITDA: $66 million for Q4, aligning with upwardly adjusted guidance; full-year adjusted EBITDA reached $276 million.
• Revenue: Consolidated revenue decreased due to a $26 million drop from non-same-unit activity, although same-unit growth was 4% with pricing up nearly 7%. Overall patient service volumes declined by just under 3%.
• Operating Cash Flow: Generated $115 million in Q4, down from $135 million year-over-year.
• Capital Deployment: $64 million used for share repurchases, reducing shares outstanding to approximately 83 million.
• Balance Sheet: Ended Q4 with $375 million in cash and net debt of just over $220 million, resulting in a net leverage ratio of under 1x.

2. Strategic Updates and Business Highlights

• Leadership Changes: New leaders appointed in key areas focused on enhancing care quality.
• Physician Alignment Programs: Introduced programs to align physician incentives with company performance, including cash bonuses tied to stock price tracking.
• Pediatrix Partners: A new initiative involving 46 physicians to enhance leadership in quality and hospital relations.
• Telemedicine Expansion: Plans to leverage telemedicine to enhance care delivery and access.

3. Forward Guidance and Outlook

• 2026 Adjusted EBITDA Guidance: Expected to be in the range of $280 million to $300 million, representing a 5% increase from 2025.
• Revenue Projections: Anticipated full-year revenue of approximately $1.9 billion, consistent with 2025.
• G&A Expenses: Forecasted to decrease slightly to $230 million to $240 million compared to $241 million in 2025.
• First Quarter Expectations: Adjusted EBITDA is expected to represent 17% to 19% of the annual target.

4. Bad News, Challenges, or Points of Concern

• Volume Declines: Notable declines in patient volumes across all service lines, attributed to tough year-over-year comparisons.
• Payer Mix Risks: Potential negative impact from the expiration of ACA subsidies, although current metrics remain steady.
• Operational Uncertainties: Difficulty in quantifying the effects of changes in government policies and payer mix on future performance.

5. Notable Q&A Insights

• Revenue Drivers: Management indicated that revenue growth for 2026 is expected to be flat in terms of volume and pricing.
• Variable Compensation: Concerns were raised about variable compensation expenses, with management noting that alignment initiatives aim to strengthen ties between physicians and the organization.
• Pricing Sustainability: While pricing has been strong, management expects it to stabilize moving into 2026, with tougher comparisons anticipated.
• M&A Opportunities: Management remains open to growth through acquisitions but emphasizes maintaining focus on core pediatrics and obstetrics strengths.

Overall, Pediatrix Medical Group reported strong financial results for Q4 2025, with a positive outlook for 2026, while also acknowledging challenges related to patient volume and potential risks from changing healthcare policies.